Non-Small Cell Carcinoma of Lung, TNM Stage 4
13
2
3
3
Key Insights
Highlights
Success Rate
43% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 90/100
30.8%
4 terminated out of 13 trials
42.9%
-43.6% vs benchmark
15%
2 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (13)
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer
Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
A Study to Investigate LYL797 in Adults With Solid Tumors
A Biomarker Screening Protocol for Participants With Solid Tumors
Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
Radiotherapy to the Primary in Metastatic Non-small Cell Lung Cancer Patients
Re-Induction After Initial Response With Immune Therapy With Radiotherapy in Lung Cancer
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Clinical and Molecular Study With Digital Support of Patients With Inoperable Lung Cancer
Endobronchial Cryotherapy in Management of MEBO in Patients With Inoperable NSCLC
Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)
A Real World Study Based on NGS (TRUMPRWS)